Literature DB >> 11235927

Melatonin in medically ill patients with insomnia: a double-blind, placebo-controlled study.

C Andrade1, B S Srihari, K P Reddy, L Chandramma.   

Abstract

BACKGROUND: It has been suggested that melatonin improves sleep functioning, but this possibility has not been studied in medical populations.
METHOD: 33 medically ill persons with initial insomnia were randomly assigned to receive either melatonin (N = 18) or placebo (N = 15) in a flexible-dose regimen. Double-blind assessments of aspects of sleep functioning were obtained daily across the next 8 to 16 days.
RESULTS: The mean stable dose of melatonin was found to be 5.4 mg. Relative to placebo, melatonin significantly hastened sleep onset, improved quality and depth of sleep, and increased sleep duration without producing drowsiness, early-morning "hangover" symptoms, or daytime adverse effects (p < .05). Melatonin also contributed to freshness in the morning and during the day and improved overall daytime functioning. Benefits were most apparent during the first week of treatment.
CONCLUSION: Melatonin may be a useful hypnotic for medically ill patients with initial insomnia, particularly those for whom conventional hypnotic drug therapy may be problematic.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11235927     DOI: 10.4088/jcp.v62n0109

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  15 in total

1.  Disturbances in melatonin, cortisol and core body temperature rhythms after major surgery.

Authors:  Ismail Gögenur; Ubbat Ocak; Omer Altunpinar; Benita Middleton; Debra J Skene; Jacob Rosenberg
Journal:  World J Surg       Date:  2007-02       Impact factor: 3.352

2.  Optimizing the Pharmacologic Treatment of Insomnia: Current Status and Future Horizons.

Authors:  Jared Minkel; Andrew D Krystal
Journal:  Sleep Med Clin       Date:  2013-09-01

3.  Sleepless in the hospital: A systematic review of non-pharmacological sleep interventions.

Authors:  Megan A Miller; Brenna N Renn; Frances Chu; Nicole Torrence
Journal:  Gen Hosp Psychiatry       Date:  2019-05-24       Impact factor: 3.238

4.  The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis.

Authors:  Nina Buscemi; Ben Vandermeer; Nicola Hooton; Rena Pandya; Lisa Tjosvold; Lisa Hartling; Glen Baker; Terry P Klassen; Sunita Vohra
Journal:  J Gen Intern Med       Date:  2005-12       Impact factor: 5.128

5.  A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease.

Authors:  Clifford Singer; Rochelle E Tractenberg; Jeffrey Kaye; Kim Schafer; Anthony Gamst; Michael Grundman; Ronald Thomas; Leon J Thal
Journal:  Sleep       Date:  2003-11-01       Impact factor: 5.849

Review 6.  Role of the melatonin system in the control of sleep: therapeutic implications.

Authors:  Seithikurippu R Pandi-Perumal; Venkatramanujan Srinivasan; D Warren Spence; Daniel P Cardinali
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

7.  Psychopharmacology for medically ill adolescents.

Authors:  Brenda Bursch; Marcy Forgey
Journal:  Curr Psychiatry Rep       Date:  2013-10       Impact factor: 5.285

Review 8.  Sleep in Hospitalized Older Adults.

Authors:  Nancy H Stewart; Vineet M Arora
Journal:  Sleep Med Clin       Date:  2017-11-10

Review 9.  Circadian sleep-wake rhythm disturbances in end-stage renal disease.

Authors:  Birgit C P Koch; J Elsbeth Nagtegaal; Gerard A Kerkhof; Piet M ter Wee
Journal:  Nat Rev Nephrol       Date:  2009-05-26       Impact factor: 28.314

10.  Molecular mechanisms underlying electroconvulsive therapy-induced amnestic deficits: A decade of research.

Authors:  Chittaranjan Andrade
Journal:  Indian J Psychiatry       Date:  2008-10       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.